BioPharm International: MHC-Associated Peptide Proteomics – Immunogenicity and Vaccine Design
Published on December 18, 2024
In article featured on BioPharm International, Campbell Bunce, CSO and Ed Cloake, Director of Immunology at Abzena look at how the MAPPs assay works, how it integrates with other immunogenicity assays, and just how it can be flipped to help in vaccine design.
Essential to the development of therapeutic proteins is immunogenicity assessment. A key step in this process that’s both powerful and versatile: major histocompatibility complex (MHC)-associated peptide proteomics (MAPPs), a complex yet informative assay that gives detailed insights into the immunogenic potential of a biologic.
MAPPS offer versatility, and are applicable to other areas of drug development like vaccine design.
Looking to the future, integrating MAPPs with other immunogenicity tools has the potential for even greater drug development precision.
Read the full article here
The post BioPharm International: MHC-Associated Peptide Proteomics – Immunogenicity and Vaccine Design appeared first on Abzena.